Legend Biotech Corp Finance Income Received Classified As Operating Activities
Legend Biotech Corp (LEGN) reported Finance Income Received Classified As Operating Activities of $52.00 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-10.
Financial Statements › Cash Flow › Operating Activities
ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities · last filed 2026-03-10
- Legend Biotech Corp finance income received classified as operating activities for the quarter ending 2025-12-31 was $10.82M, a 10.59% increase year-over-year.
- Legend Biotech Corp finance income received classified as operating activities for the quarter ending 2025-09-30 was $3.28M, a 60.18% decline year-over-year.
- Legend Biotech Corp finance income received classified as operating activities for the quarter ending 2025-06-30 was $22.95M, a 295.25% increase year-over-year.
- Legend Biotech Corp finance income received classified as operating activities for the quarter ending 2025-03-31 was $14.96M, a 10.97% increase year-over-year.
| Period end | Finance Income Received Classified As Operating Activities 3 month | Finance Income Received Classified As Operating Activities 6 month | Finance Income Received Classified As Operating Activities 9 month | Finance Income Received Classified As Operating Activities 12 month | Finance Income Received Classified As Operating Activities 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $10.82M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $14.10M derived: sum of 2 quarters · filed 2026-03-10 | $37.04M derived: sum of 3 quarters · filed 2026-03-10 | $52.00M 20-F · filed 2026-03-10 | |
| 2025-09-30 | $3.28M derived: 6-K 9 month − 6-K 6 month · filed 2025-11-12 | $26.23M derived: sum of 2 quarters · filed 2025-11-12 | $41.18M 6-K · filed 2025-11-12 | $50.96M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2025-06-30 | $22.95M derived: 6-K 6 month − 6-K 3 month · filed 2025-08-11 | $37.91M 6-K · filed 2025-08-11 | $47.69M derived: sum of 3 quarters · filed 2026-03-10 | $55.92M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2025-03-31 | $14.96M 6-K · filed 2025-05-13 | $24.74M derived: sum of 2 quarters · filed 2026-03-10 | $32.97M derived: sum of 3 quarters · filed 2026-03-10 | $38.78M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-12-31 | $9.78M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $18.02M derived: sum of 2 quarters · filed 2026-03-10 | $23.82M derived: sum of 3 quarters · filed 2026-03-10 | $37.30M 20-F · filed 2026-03-10 | $37.34M 20-F · filed 2025-03-11 |
| 2024-09-30 | $8.23M derived: 6-K 9 month − 6-K 6 month · filed 2025-11-12 | $14.04M derived: sum of 2 quarters · filed 2025-11-12 | $27.52M 6-K · filed 2025-11-12 | $41.92M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-06-30 | $5.81M derived: 6-K 6 month − 6-K 3 month · filed 2025-08-11 | $19.29M 6-K · filed 2025-08-11 | $33.68M derived: sum of 3 quarters · filed 2026-03-10 | $49.96M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2024-03-31 | $13.48M 6-K · filed 2025-05-13 | $27.88M derived: sum of 2 quarters · filed 2026-03-10 | $44.16M derived: sum of 3 quarters · filed 2026-03-10 | $56.84M derived: sum of 4 quarters · filed 2026-03-10 | |
| 2023-12-31 | $14.40M derived: 20-F 12 month − 6-K 9 month · filed 2026-03-10 | $30.68M derived: sum of 2 quarters · filed 2026-03-10 | $43.37M derived: sum of 3 quarters · filed 2026-03-10 | $47.30M 20-F · filed 2026-03-10 | $47.27M 20-F · filed 2024-03-19 |
| 2023-09-30 | $16.28M derived: 6-K 9 month − 6-K 6 month · filed 2024-11-12 | $28.97M derived: sum of 2 quarters · filed 2024-11-12 | $32.90M 6-K · filed 2024-11-12 | $36.68M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-06-30 | $12.69M derived: 6-K 6 month − 6-K 3 month · filed 2024-08-09 | $16.62M 6-K · filed 2024-08-09 | $20.40M derived: sum of 3 quarters · filed 2025-03-11 | $21.68M derived: sum of 4 quarters · filed 2025-03-11 | |
| 2023-03-31 | $3.94M 6-K · filed 2024-05-13 | $7.71M derived: sum of 2 quarters · filed 2025-03-11 | $8.99M derived: sum of 3 quarters · filed 2025-03-11 | ||
| 2022-12-31 | $3.78M derived: 20-F 12 month − 6-K 9 month · filed 2025-03-11 | $5.06M derived: sum of 2 quarters · filed 2025-03-11 | $5.58M 20-F · filed 2025-03-11 | ||
| 2022-09-30 | $1.28M derived: 6-K 9 month − 6-K 6 month · filed 2023-11-20 | $1.80M 6-K · filed 2023-11-20 | |||
| 2022-06-30 | $524.00K 6-K · filed 2023-08-15 | ||||
| 2021-12-31 | $652.00K 20-F · filed 2024-03-19 | ||||
| 2021-06-30 | $145.00K 6-K · filed 2021-08-23 | ||||
| 2020-12-31 | $3.37M 20-F · filed 2023-03-30 | ||||
| 2020-06-30 | $529.00K 6-K · filed 2021-08-23 | ||||
| 2019-12-31 | $9.02M 20-F/A · filed 2023-02-17 | ||||
| 2018-12-31 | $1.80M 20-F · filed 2021-04-02 |